Novel Agent Enfortumab, a Nectin-4 Inhibitor, for Transitional Cell Carcinoma of the Bladder: Highlights from ASCO 2018 (BMIC-049)

Novel Agent Enfortumab, a Nectin-4 Inhibitor, for Transitional Cell Carcinoma of the Bladder: Highlights from ASCO 2018 (BMIC-049)

BeaconMedIC

1 year
102 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Dr. Daniel Goldstein reviews provocative and highly promising results with enfortumab, an inhibitor of nectin-4, as a treatment for advanced transitional cell carcinoma of the bladder.
Up Next Autoplay